Why Affimed Stock Is Heating Up Today

What has happened

AFMD Stock : The shares of German cancer immunotherapy firm Affimed (AFMD 4.27 percent) increased by healthy 7.1 percent as of 11:59 a.m. ET Monday. The biotech’s stock was moving higher following an update on the clinical trial for its primary blood cancer treatment AFM13.

AFM13 is an tetravalent bispecific antibody which connects natural killer cells to cancer cells. Affimed presented its most recent information on progress through an oral presentation during the annual American Association for Cancer Research conference on the weekend.

So , what’s next?

Three of the highlights from the presentation are an effective way to draw investors’ attention to this stock Monday morning:

1. AFM13 When used in conjunction with pre-complexed natural killer cells that are derived from blood generated an objective 100% response rate in patients suffering from CD30-positive, relapsed or refractory Hodgkin and non-Hodgkin lymphomas.
2. The treatment’s total response rate was at an astounding 62% after a second treatment cycle in 13 patients who received the dosage recommended for the phase 2.
3. Additionally it was that the treatment was remarkably tolerated for a brand new cell therapy, and there were no instances of cytokine release syndrome or any other adverse reactions reported so far.

What do we do now?

The stock of Affimed does appear to be a worthy speculation buy following the release of the latest test results.

The short and the long aspect is cancer patients who participated in the study were relapsed after numerous previous treatment options. However, Affimed’s innovative anti-cancer treatment is still able to offer an evident clinical benefit to this patient group. This is a positive indication that AFM13 performs as expected.

The main announcement, however, is expected to be when the company announces the results of its phase 2 study of AFM13 as a single therapy for patients suffering from relapsed or refractory peripheral T-cell lymphoma that is CD30 positive. This data release is expected to be released during the second half of the year.

Affimed Returns vs. S&P